Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Late-Stage Sickle Cell Disease Study Splits on Main Goals

(MedPage Today) -- The thalassemia drug mitapivat (Aqvesme) significantly improved hemoglobin response in patients with sickle cell disease but failed to top placebo when it came to reducing pain crises in a phase III trial that aims to support...

Late-Stage Sickle Cell Disease Study Splits on Main Goals

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Monday 2 November →